Karim Selmi

Karim Selmi

Auto-generated profile, based on publicly available information

Karim Selmi

Austrian Red Cross Research, OeRK Vienna Austria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2026 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
AAAndré Cronemberger Andrade
André Cronemberger Andrade
RPRodolphe William Poupardin
Rodolphe William Poupardin
MWMartin Wolf
Martin Wolf
LPLiliia Paniushkina
Liliia Paniushkina
KSKarim Selmi
Karim Selmi
DSDirk Strunk
Dirk Strunk
Extracellular vesicles (EVs) mediate cell‐to‐cell communication in development, health and disease. Heparin is a common component in human induced pluripotent stem cell (hiPSC) media but its impact on hiPSC‐EVs beyond stabilizing growth factors is unknown. Published evidence indicates heparin dose‐dependent EV uptake inhibition in heterotypic target cells. We asked if heparin affects hiPSC‐EV yield, storage, phenotype, or function. We used large‐scale hiPSC‐EV propagation to obtain pro‐angiogenic hiPSC‐EVs in presence or absence of escalating heparin doses and determined EV quantity, identity and functionality. Heparin delayed hiPSC colony‐confluence without significantly affecting hiPSC viability, pluripotency markers and proliferation. Significantly elevated tetraspanin + /flotillin + hiPSC‐EV number (mean 367±31 EVs/cell/24 h at 200 IU heparin/mL) enabled efficient purification of > 10 11 /mL functional EVs at superior particle/protein ratio > 10 10 /mg. Heparin dose‐dependently inhibited EV uptake in hiPSC and endothelial progenitors, comparable to 5 IU/mL flavobacterium heparinase, and increased EV recovery after storage in NaCl but not in cell‐conditioned media. EVs obtained from hiPSC at 1% O 2 with 200 IU/mL heparin maintained superior angiogenesis similarly to control hiPSC‐EVs obtained without heparin. We conclude that heparin inhibits hiPSC‐EV reuptake and stabilizes NaCl‐cryopreserved EVs thus boosting EV recovery while maintaining pro‐angiogenic function. Heparin presence and dose should therefore be documented particularly in PSC media.